Multiple Myeloma Knowledge Hub

Sepsis-Associated Mortality Unlikely to be Prevented Through Enhanced Hospital-Based Care

Nearly Half of Patients with Multiple Myeloma Die in the Hospital

Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) die in the hospital,...

Daratumumab Monotherapy Safe in Heavily Treated Relapsed or Refractory Multiple Myeloma

An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily treated relapsed or refractory multiple...
FDA Approves Nubeqa® for Prostate Cancer

Melflufen Combination Approved for Heavily Pretreated Multiple Myeloma

On March 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (melflufen) in combination with dexamethasone for the treatment...

Hem/Onc Roundup: Eliminating Disparity in MM Trials; Plus, Cancer Care in the Pandemic

This week, researchers from the Dana-Farber Cancer Institute collaborated with the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research...

Economic Burden of Late-Stage Multiple Myeloma Treatment

A study published online in the Journal of Oncology Pharmacy Practice calculated economic outcomes of patients with relapsed/refractory multiple myeloma (RRMM) in the first...
A Lack of Racial Diversity Exists in Cancer Drug Clinical Trials

New Recommendations to Improve Racial Disparities in MM Drug Trials

In a collaborative effort, researchers from the Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA), and the American Association for Cancer Research...

Hem/Onc Roundup: Financial Toxicity in MM Treatment, Personalizing Cancer Care, and More

This week on DocWire, editors spoke with Dr. Parameswaran Hari, Hematology Chief at the Medical College of Wisconsin, about financial toxicity associated with chimeric...
Advertisement

Journal Reading List

Advertisement
Advertisement